Thornton
USDC transfer volume hit 5X USDT’s in fallout from FTX collapse
Stablecoin USD Coin (USDC) has grown in popularity since the collapse of FTX. It now frequently reaches daily transfer volumes four to five times that recorded by major competitor Tether (USDT) according to data from blockchain analytics firm Glassnode. That’s despite the market cap of USDT being $23 billion greater than USDC. As of Jan. 10, the difference was in USDC’s favor by a margin of four and a half times. Both stablecoins recorded surges in transfer volumes following an infamous tweet from Binance CEO Changpeng Zhao on Nov. 6 announcing Binance would liquidate its entire FTX Token (FTT) holdings. FTX went into bankruptcy soon after. Since then, USDC has been the preferred choice for crypto users, averaging over $12.5 billion more in transfer volume per day than USDT, according to G...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
